Press releases
- Orexo extends patent protection for its nasal epinephrine powder product OX640 in the US
- Orexo announces that the condition for early redemption of its existing bonds has been fulfilled
- Orexo publishes the Annual and Sustainability Report for 2023
- Correction: Notice of Annual General Meeting of Orexo
- Notice of Annual General Meeting of Orexo
- Orexo successfully issues senior secured callable floating rate social bonds of SEK 500 m and announces results of the tender offer for its existing bonds
- Orexo contemplates issuance of senior secured callable floating rate social bonds and announces a conditional tender offer for its existing bonds
- Orexo strengthens its sustainability work by establishing a social financing framework
- Orexo and Sobi agree to advance feasibility study with AmorphOX
- Orexo Interim Report Q4 2023, incl. Full Year Report
More ▼
Key statistics
On Tuesday, Orexo AB (C5G:FRA) closed at 1.31, -18.73% below its 52-week high of 1.61, set on Jul 21, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 1.31 |
---|---|
High | 1.31 |
Low | 1.31 |
Bid | 1.38 |
Offer | 1.48 |
Previous close | 1.37 |
Average volume | 0.00 |
---|---|
Shares outstanding | 34.71m |
Free float | 27.39m |
P/E (TTM) | -- |
Market cap | 547.73m SEK |
EPS (TTM) | -3.73 SEK |
Data delayed at least 15 minutes, as of Apr 23 2024 07:13 BST.
More ▼